Selective Factor XI Inhibitors for Thrombosis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for thrombosis and related conditions, such as thromboembolic disorders, are inadequate in inhibiting Factor XI activation, which is a key component in the blood coagulation process, leading to potentially life-threatening blood clots and other complications.
Innovation Solution
Development of selective Factor XI activation inhibitors, represented by compounds of Formula I, which can be administered to inhibit Factor XI activation and thereby reduce blood clot formation and associated conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for thrombosis, then blood clot formation is not adequately inhibited, but Factor XI activation inhibition is insufficient
Solution Approach 1:
The patent introduces Factor XI activation inhibitors as intermediary compounds that specifically target and block the activation of Factor XI, preventing its conversion to active Factor XIa. This intermediary substance interrupts the clotting cascade at a critical point, thereby reducing thrombus formation without completely blocking all coagulation pathways.
Solution Approach 2:
The invention modifies the pharmacokinetic parameters of Factor XI inhibition by developing compounds with optimized half-life, potency, and selectivity. The patent describes compounds that achieve sustained inhibition of Factor XI activation with improved pharmacokinetic profiles, including extended duration of action and reduced dosing frequency compared to previous treatments.
2Object-affected harmful factors
If Factor XI activation is inhibited, then thrombosis risk is reduced, but existing treatments lack therapeutic benefit
Solution Approach 1:
The patent describes Factor XI activation inhibitors as transient therapeutic agents that temporarily block Factor XI activation during periods of elevated thrombosis risk. These compounds provide time-limited protection against clot formation, allowing the body's natural coagulation system to remain functional when needed while preventing pathological clotting during high-risk periods.
3Strength
If blood coagulation is enhanced for homeostasis, then blood loss control is improved, but abnormal coagulation causes thrombosis
Solution Approach 1:
The patent introduces selective inhibition of Factor XI activation that locally targets the intrinsic coagulation pathway without affecting the extrinsic pathway or platelet function. This localized intervention allows normal hemostatic clotting at injury sites while preventing abnormal thrombus formation in the vascular system, achieving spatially differentiated control of coagulation.
Solution Approach 2:
The invention implements partial inhibition of the coagulation cascade by specifically blocking Factor XI activation while allowing other coagulation factors to remain active. This partial action maintains sufficient clotting capability for hemostasis while preventing the excessive coagulation that leads to thrombosis, achieving a balanced state between protection and prevention.
Data Source
AI summary
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.